1d:I[2890,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1e:I[1318,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1f:T45e,

The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.

The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.

Review clips: Yahoo Finance, CNBC

Hosted on Acast. See acast.com/privacy for more information.

20:T4e6,[{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Podcasts","item":"https://metacast.app/podcasts"},{"@type":"ListItem","position":2,"name":"Business","item":"https://metacast.app/podcasts/categories/business"},{"@type":"ListItem","position":3,"name":"Behind the Money","item":"https://metacast.app/podcasts/3b270507-35a4-5cdc-

‌

Episode description

Moderna’s race to the vaccine

Episode description